The final report of post-marketing surveillance for cetuximab in colorectal cancer in Japan

被引：0
|
作者：
Yamaguchi, K.
Satoh, T.
Watanabe, T.
Ishiguro, M.
Maruyama, K.
Seriu, T.
Miki, T.
Ito, H.
Sugihara, K.
Sakata, Y.
机构：
[1] Saitama Canc Ctr, Saitama, Japan
[2] Kinki Univ, Sch Med, Osaka 589, Japan
[3] Teikyo Univ, Sch Med, Dept Surg, Tokyo 173, Japan
[4] Tokyo Med & Dent Univ, Grad Sch, Dept Surg Oncol, Tokyo, Japan
[5] Bristol Myers KK, Tokyo, Japan
[6] Merck Serono, Tokyo, Japan
[7] Misawa Municipal Hosp, Misawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 04期
关键词：
D O I：
10.1200/jco.2011.29.4_suppl.590
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
590
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Post-marketing device safety surveillance
    Vidi, Venkatesan D.
    Matheny, Michael E.
    Resnic, Frederic S.
    CONTEMPORARY CLINICAL TRIALS, 2011, 32 (03) : 307 - 308
  • [42] Post-marketing stability surveillance: Amoxicillin
    Naidoo, K. K.
    Nompuku, P.
    Mkalali, S. N.
    Shabangu, K.
    Nkabinde, L.
    Singh, V
    SOUTH AFRICAN FAMILY PRACTICE, 2006, 48 (06) : 14 - +
  • [43] Sodium Oxybate Post-Marketing Surveillance
    Feldman, Neil T.
    JOURNAL OF CLINICAL SLEEP MEDICINE, 2011, 7 (04): : 417 - 417
  • [44] POST-MARKETING SURVEILLANCE OF MEDICINES IN THE UK
    GRIFFIN, JP
    BAKER, R
    PHARMACY INTERNATIONAL, 1981, 2 (09): : 203 - 209
  • [45] Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
    Sakata, Yukinori
    Matsuoka, Toshiyuki
    Ohashi, Satoshi
    Koga, Tadashi
    Toyoda, Tetsumi
    Ishii, Mika
    DRUGS-REAL WORLD OUTCOMES, 2019, 6 (01) : 27 - 35
  • [46] Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
    Yukinori Sakata
    Toshiyuki Matsuoka
    Satoshi Ohashi
    Tadashi Koga
    Tetsumi Toyoda
    Mika Ishii
    Drugs - Real World Outcomes, 2019, 6 : 27 - 35
  • [47] Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan
    Ninomiya, Haruhiko
    Obara, Naoshi
    Chiba, Shigeru
    Usuki, Kensuke
    Nishiwaki, Kaichi
    Matsumura, Itaru
    Shichishima, Tsutomu
    Okamoto, Shinichiro
    Nishimura, Jun-ichi
    Ohyashiki, Kazuma
    Nakao, Shinji
    Ando, Kiyoshi
    Kanda, Yoshinobu
    Kawaguchi, Tatsuya
    Nakakuma, Hideki
    Harada, Daisuke
    Akiyama, Hirozumi
    Kinoshita, Taroh
    Ozawa, Keiya
    Omine, Mitsuhiro
    Kanakura, Yuzuru
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 104 (05) : 548 - 558
  • [48] Safety analysis of Epzicom ® (lamivudine/abacavir sulfate) in post-marketing surveillance in Japan
    Kurita, Tomoko
    Kitaichi, Tomomi
    Nagao, Takako
    Miura, Toshiyuki
    Kitazono, Yoshifumi
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 (04) : 372 - 381
  • [49] Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan
    Haruhiko Ninomiya
    Naoshi Obara
    Shigeru Chiba
    Kensuke Usuki
    Kaichi Nishiwaki
    Itaru Matsumura
    Tsutomu Shichishima
    Shinichiro Okamoto
    Jun-ichi Nishimura
    Kazuma Ohyashiki
    Shinji Nakao
    Kiyoshi Ando
    Yoshinobu Kanda
    Tatsuya Kawaguchi
    Hideki Nakakuma
    Daisuke Harada
    Hirozumi Akiyama
    Taroh Kinoshita
    Keiya Ozawa
    Mitsuhiro Omine
    Yuzuru Kanakura
    International Journal of Hematology, 2016, 104 : 548 - 558
  • [50] Interim analysis of post-marketing surveillance of ravulizumab for paroxysmal nocturnal hemoglobinuria in Japan
    Usuki, Kensuke
    Ikezoe, Takayuki
    Ishiyama, Ken
    Kanda, Yoshinobu
    Gotoh, Akihiko
    Hayashi, Hideo
    Shimono, Akihiko
    Kitajima, Akiyo
    Obara, Naoshi
    Nishimura, Jun-ichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 118 (03) : 311 - 322
12345